Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Funded by the Bill and Melinda Gates Foundation, the TACT-CV study (2017-2020) is a multi-centre, open-label randomised trial to assess the efficacy, safety and tolerability of the Triple ACT artemether-lumefantrine+amodiaquine (AL+AQ) compared to the ACT artemether-lumefantrine (AL) in uncomplicated falciparum malaria in Cambodia and Vietnam that will run to 2020.

Mother and baby participating in TACT CV Study © MORU 2019, Nicky Almasy
A Cambodian mother and child with a TACT-CV study doctor in Siem Pang, Cambodia.

TACT-CV's Principal Investigator is Professor Arjen Dondorp, and the study in Cambodia is coordinated for MORU by Rupam Tripura, James Callery, Thomas Peto, and Professor Lorenz von Seidlein.

Malaria is endemic in many rural areas of Stung Treng, a province of over 110,000 people in the northeast of Cambodia bisected by the Mekong River and bordering Laos. In 2017, in partnership with the Cambodian National Centre for Parasitology, Entomology, and Malaria Control (CNM) MORU established a research station at Siem Pang health centre. The site features a study ward, offices, accommodation, and laboratory facilities – and is the Cambodia site for TACT-CV.

School children inside a classroom in Siem Pang© MORU 2019, Nicky Almasy.

Epidemiological studies in nearby villages map malaria and look at transmission patterns and understand forest-acquired malaria in collaboration with Professor Richard Maude, head of MORU Epidemiology.

In addition, public engagement activities providing health education in rural communities are coordinated by Nou Sanann and Pich Kunthea in collaboration with Professor Phaik Yeong Cheah, Head of MORU Bioethics.